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ApoptosisSYK (spleen tyrosine kinase) iswell-characterized in the immune system as an essential enzyme required for sig-
naling throughmultiple classes of immune recognition receptors. As a modulator of tumorigenesis, SYK has a bit
of a schizophrenic reputation, acting in some cells as a tumor promoter and in others as a tumor suppressor. In
many hematopoietic malignancies, SYK provides an important survival function and its inhibition or silencing
frequently leads to apoptosis. In cancers of non-immune cells, SYK provides a pro-survival signal, but can also
suppress tumorigenesis by restricting epithelial–mesenchymal transition, enhancing cell–cell interactions and
inhibiting migration.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The autonomous growth of cancer cells is driven by an array of mu-
tations, ampliﬁcations, rearrangements and modiﬁcations affecting
hundreds of distinct genes. Only a limited number of these genes ex-
press proven, effectively druggable targets. Prominent among these
are protein kinases, important components of the signal transduction
machinery of eukaryotic cells that regulate the interactions of the cell
with its environment and control such processes as energymetabolism,
cell cycle progression, cytoskeletal rearrangement, gene expression and
apoptosis. Tyrosine-protein kinases, which account for 17% of the
human kinome, are particularly attractive drug targets due to their inti-
mate involvement with the regulation of cell proliferation and survival
and their frequent association with tumorigenesis [1,2]. Thus, a number
of therapeutic agents targeted against tyrosine kinases including ima-
tinib (Gleevec) for the inhibition of BCR-ABL, geﬁtinib (Iressa) and erlo-
tinib (Tarceva) for targeting activated mutants of the epidermal growth
factor receptor (EGFR) and trastuzumab (Herceptin) for the inhibition
of human epidermal growth factor receptor-2 (HER2) are important
components of the oncologist's armamentarium [1].While a role inma-
lignant transformation for many tyrosine kinases is well documented,
the ability of others to modulate the growth properties of cancer cells
is less well understood. SYK (spleen tyrosine kinase) is a prime examplenal Chemistry and Molecular
es Research Building, 210 S,since both tumor promoting and tumor suppressing roles for this en-
zyme have been described.
SYK was originally isolated by our group from bovine thymus [3,4]
and by the Yamamura group from porcine spleen [5]. These tissue
sources are consistent with expression analyses, which conﬁrm that
SYK is expressed at highest levels in cells of hematopoietic origins
[6–8]. SYK functions as an essential component of the signalingmachin-
ery of multiple receptors in the immune system that play important
roles in distinguishing self from nonself [9]. SYK contains a tandem
pair of SH2 (Src homology 2) domains at the N-terminus that are sepa-
rated from each other by a linker A region [10]. A longer linker B region
separates the SH2 domains from the catalytic domain. Structural analy-
ses indicate that hydrophobic residues in linker A, linker B and the cat-
alytic domain interact to restrict SYK to a largely autoinhibited
conformation [11]. SYK is activated when it is recruited to an immune
recognition receptor through the binding of its SH2domains to a doubly
phosphorylated immunoreceptor tyrosine-based activation motif or
ITAM, a sequence of amino acids found on most SYK-coupled receptors
[12]. ITAMs consist of two sets of YXXL/I sequences separated by 6–10
amino acids. Examples of receptors possessing ITAM-containing com-
ponents include the B cell receptor for antigen (BCR); receptors for IgE
(FcεRI), IgG (FcγRIIa) and IgA (FcαRI), the collagen receptor of platelets
(GPVI) as well as NK cell activating receptors and integrins that signal
through associated DAP12 or FcRγ components. Following receptor en-
gagement and clustering, amember of the Src-family of tyrosine kinases
catalyzes the phosphorylation of the more N-terminal tyrosine within
the ITAM to initiate the recruitment of SYK to the receptor [9,13]. Phos-
phorylation of the second ITAM tyrosine, likely by SYK, completes the
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ed ITAMs relieves autoinhibition to activate SYK [11], which then cata-
lyzes the phosphorylation of protein substrates primarily on tyrosines
located in sites rich with acidic amino acids [13] (however, recent evi-
dence has shown that SYK also has the ability to phosphorylate some
proteins on serine [14,15]). SYK itself has multiple tyrosines that be-
come phosphorylated that regulate its activity and its ability to partici-
pate in protein–protein interactions [13]. Substrates for SYK consist of
adaptor/scaffolding proteins such as BLNK, SLP76 and LAT, andmultiple
regulatory enzymes that include lipid kinases, phospholipases and gua-
nine nucleotide exchange factors [9,13]. These phosphorylations serve
to couple liganded receptors to the activation of signaling cascades
that include the PI3K/AKT/mTOR, Ras/ERK, PLCγ/NFAT, and IKK/NFκB
pathways. These, in turn, are important modulators of metabolism and
gene transcription that determine the physiological responses of an im-
mune cell to receptor engagement. The critical involvement of SYK in
the activation of immune cells has made it a popular target for anti-
inﬂammatory therapeutics directed against such diseases as allergic
asthma, rheumatoid arthritis, lupus erythematosus and thrombocyto-
penic purpura [16].
In addition to SYK's presence in most hematopoietic cells, there are
multiple reports of SYK in various cell types outside of the immune sys-
tem, particularly in epithelial cells from a variety of organs [17,18]
where it is present generally at much lower levels [6–8]. For example,
SYK is present in epithelial cells of the breast at levels at least 6-fold
lower than in inﬁltrating immune cells [19]. However, Syk
haploinsufﬁcient mice exhibit increased ductal outgrowth, suggesting
an important role for SYK in tissue homeostasis in the breast [20].
There also are many examples of individual cell lines that are not of he-
matopoietic origin that have levels of SYK mRNA as high as or even
higher than those found in lymphoid cell lines [8].
2. SYK as a tumor promoter
2.1. SYK and cell survival signaling downstream of the BCR in hematopoietic
malignancies
Much of the attention on SYK as a promoter of cancer cell growthhas
focused onmalignancies of B cell origins and the role of tonic or chronic
signaling from the BCR in the maintenance of tumor cell viability. Dur-
ing the course of B cell development in the bonemarrow, successful re-
arrangement of the immunoglobulin heavy chain locus yields a pre-B
cell receptor that contains the heavy chain, surrogate light chains and
an associated heterodimer of CD79a and CD79b,which are the signaling
subunits that contain the ITAM sequences [21]. Successful gene rear-
rangement and receptor assembly are required for cells to survive the
pro- to pre-B cell transition through signals sent from the pre-BCR via
SYK. Consequently, SYK-deﬁcient B cell precursors largely fail to prog-
ress to the pre-B cell stage of development [22]. Those that do make
the transition, mainly through the expression of low levels of the SYK-
family kinase, ZAP-70, fail to progress further to become mature B
cells [23]. This latter transition requires rearrangement of the light
chain locus and the production and expression at the cell surface of a
mature B cell receptor, again associated with the CD79a and CD79b sig-
naling components. At this stage of development, SYK is again required
for cell survival and is thought to be activated by tonic signaling
(i.e., signaling in the absence of antigen) from the assembled BCR com-
plex [21]. In fact, sustained BCR expression and tonic signaling are re-
quired for the continued survival of mature B cells [24]. Signaling
through the BAFF (B cell-activating factor) receptor, a tumor necrosis
factor (TNF)-family receptor required for follicular B cell survival, also
co-opts SYK, the BCR and its ITAMs as part of its mechanism to promote
cell survival [25].
In amousemodel of non-Hodgkin lymphoma,mice bearing both a c-
Myc oncogene driven by an immunoglobulin enhancer (Eμ-MYC) and a
HEL speciﬁc BCR (BCRHEL) develop lymphoid tumors that are reliant ontonic BCR signaling for survival [26]. Further introduction of a soluble
hen egg lysozyme transgene to generate an Eμ-MYC/BCRHEL/sHEL
mouse results in the appearance of more aggressive tumors that are
chronically activated through the BCR and resemble Burkitt's lympho-
ma. This supports the concept that either tonic or chronic signaling
through the BCR contributes to tumorigenesis. In both tumor types,
the silencing of SYK expression induces apoptosis and inhibits tumor
formation in mice.
A prime example of a role for SYK and the BCR in tumorigenesis is B
cell chronic lymphocytic leukemia (B-CLL). B-CLL arises due to the clon-
al expansion of phenotypically mature B cells. B-CLL cells are typically
BCR positive and fall into two general classes: an indolent form with
mutated immunoglobulin variable heavy chain region (IgVH) genes
and a clinically aggressive formwith unmutated IgVH genes that also ex-
press the SYK-family kinase, ZAP-70 [27]. ZAP-70 is not normally found
in B cells and its ability to enhance tumorigenesis in B-CLL does not re-
quire it to be catalytically active, suggesting a scaffolding function for
the enzyme [28]. Cells of both classes are characterized by the presence
of elevated levels of constitutively active SYK [29]. Whether SYK activa-
tion occurs due to BCR engagement by an unknown antigen through
chronic signaling—the IgM repertoire of B-CLL samples is less polymor-
phic than one would expect from random gene rearrangements—or
from ligand-independent tonic signaling from the assembled BCR com-
plex is not completely clear, although either mechanism may drive
tumor development [30].
The inhibition of SYK activity or the silencing of SYK expression in
both indolent and aggressive B-CLL triggers apoptosis by the conven-
tional mitochondrial/caspase 3 pathway [29,31,32]. The highly malig-
nant, unmutated class of cells is particularly dependent on the activity
of SYK for survival [31]. In a phase 1/2 clinical trial of the SYK inhibitor
fostamatinib, 55% of human patients with B-CLL had a positive response
to therapy [33]. Cells from treated patients exhibited a reduced proﬁle of
BCR-mediated activation events including decreased expression of NF-
κB and c-Myc target genes, reduced activation of BTK (a tyrosine kinase
activated downstreamof SYK), lowered levels ofMYC and JUNB, andde-
creased expression of cell surface activationmarkers, all consistentwith
an inhibition of BCR signaling [34].
BCR-dependent signaling also is involved in diffuse large B cell lym-
phoma (DLBCL). DLBCL is a heterogeneous collection of malignancies, a
subset of which are BCR positive, display gene expression signatures
consistent with anti-IgM-activated B cells and are reliant for survival
on the expression of components of the BCR complex [35]. Many
DLBCL cell lines exhibit tonic or chronic signaling from the BCR that re-
sults in the constitutive phosphorylation of SYK on activation loop tyro-
sines [36]. An evaluation of 61 DLBCL tumor samples from human
patients found that 44% had elevated levels of phosphorylated SYK;
and this phosphorylated SYK was localized to the plasma membrane
where BCR complexes are found [37]. A fraction of primary DLBCL sam-
ples exhibit increases in SYK gene copy number, which correlates with
increased protein expression [38]. BCR-dependent DLBCL cells also fre-
quently overexpress the transcriptional repressor, BCL6, which
downregulates the expression of PTPROt, a receptor-type protein tyro-
sine phosphatase and negative regulator of SYK-dependent BCR-
signaling [39]. Thus, a decrease in PTPROt expression enhances tonic
signaling from the BCR [40]. The SYK inhibitors R406 and PRT318 are cy-
totoxic or cytostatic for most BCR-positive DLBCL cells [36,37]. The
knockdown of SYK by siRNA arrests cell cycle progression in PRT318-
sensitive DLBCL cell lines, which phenocopies the effects of the SYK in-
hibitor [37]. Consistent with these observations, a positive response
rate of 22% for DLBCL patients was observed in a clinical trial of
fostamatinib [33].
The constitutive activation of SYK also has been reported in other B
cell-derived malignancies including follicular lymphoma (FL) [41],
mantle cell lymphoma (MCL) [42] and marginal zone lymphoma
(MZL) [43]. Primary FL cells are hyperresponsive to BCR engagement
as compared to tumor-inﬁltrating, but nonmalignant B cells [44]. In
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quently overexpressed due to gene ampliﬁcations in both cell lines
and primary tumor samples [42]. In splenic MZL, SYK expression also
is upregulated [43], potentially due to the downregulation of miR-27b
and miR-377 microRNAs, which are predicted to modulate SYK gene
transcription [45]. In both FL and MCL, the SYK inhibitor, piceatannol,
is toxic to cells expressing constitutively active, phosphorylated SYK.
In summary, the accumulating evidence indicates that SYK is clearly
an importantmediator of tonic and chronic signaling through the BCR in
multiple B cell-derived lymphomas where it plays a major role to sup-
port cell survival.
2.2. SYK and cell survival signaling downstream of receptors other than the
BCR in hematopoietic malignancies
A role for SYK in supporting tumor cell growth is not restricted to
cells expressing ITAM-containing components of the BCR complex. In
B cell acute lymphocytic leukemia (B-ALL) a large percentage of malig-
nant cells are derived from pro-B cells that lack pre-BCR or BCR com-
plexes. However, these tumor cells survive and develop many
characteristics of pre-B cells even in the absence of the pre-BCR [46]. In-
terestingly, most B-ALL cells and primary isolates from patients still
have elevated levels of constitutively active, phosphorylated SYK and
their growth both in culture and in tumor xenografts is attenuated by
inhibitors of SYK activity [46–48]. The expression of SYK can be detected
in 94% of peripheral T cell lymphomas (PTCLs) and immunoblotting ex-
periments indicate that the kinase is constitutively phosphorylated in
these cells [49]. The signals that act upstream of SYK to enhance its ac-
tivity in B-ALL and PTCL remain to be identiﬁed, although the T cell an-
tigen receptor (TCR) is a clear suspect in PTCL [50].
In some lymphoid cancers, ITAM-containing proteins other than
components of the BCR-signaling complex support the activation of
SYK to promote cancer cell survival. During the latent stage of infection,
Epstein–Barr virus (EBV) expresses the integral membrane protein
LMP2A [51]. LMP2A interacts with both Lyn and SYK, the latter through
an N-terminal ITAM that, when phosphorylated, stably associates with
SYK's tandem pair of SH2 domains. These interactions inhibit signaling
through the BCR and prevent lytic replication. Interestingly, LMP2A
serves as a surrogate BCR to promote B cell differentiation even in the
absence of cell surface immunoglobulins by providing the tonic signals
required for B cell survival [52]. Thus, B cells expressing LMP2A can pop-
ulate lymphoid organs even in Rag-1-deﬁcient mice. While EBV infec-
tions are nearly universal in adults, these are effectively controlled by
a cytotoxic T cell response. However, EBV infections uncontrolled by
adaptive immune responses in immunocompromised individuals can
result in EBV+ post-transplant lymphoproliferative disorder (PTLD).
The resulting mainly B cell-derived lymphomas are characterized by
the appearance of constitutively active SYK [53]. Most are dependent
on SYK expression and activity for survival as both siRNAs directed
against SYK mRNA and the SYK inhibitor R406 induce apoptosis in
these cells.
In acute myeloid leukemia (AML), integrins can function upstream
of SYK to enhance its activity and support tumor cell growth. AML arises
from the enhanced proliferation and defective differentiation of progen-
itor cells of the myeloid lineage and thus does not typically express
components of the BCR complex. An investigation of the sensitivity of
AML cells to inhibitors of EGFR (which is not expressed in AML),
coupledwith a siRNA screen, identiﬁed SYK as a key player in AML path-
ogenesis [54]. Both siRNAs and inhibitors targeting SYK decrease prolif-
eration and induce differentiation of AML cell lines and primary AML
blasts and inhibit the growth of AML xenografts in mice [54]. One clue
to the upstream activator of SYK in AML came from a shRNA-based
screen that identiﬁed β3-integrin (ITGB3) as an important factor
supporting the proliferation and inhibiting the differentiation of AML
[55]. Downregulation of ITGB3 expression by RNA interference
decreases the level of phosphorylated and activated SYK and mimicsthe effects of SYK inhibitors on AML proliferation and differentiation.
Another clue came from a mass spectrometric-based analysis of SYK-
interacting proteins in AML cells that identiﬁedMac-2 (β2αM integrin)
and FcγRI as key SYK-binding partners [56]. The engagement of either
receptor is coupled to the activation of SYK. Interestingly, the knock-
down of CD18 (β2-integrin) or of the FcRγ chain attenuates the SYK-
dependent proliferation of AML cell lines. In both neutrophils and mac-
rophages, the integrin-mediated activation of SYK requires the expres-
sion of either DAP12 or FcRγ (FCER1G) [57], both of which contain
ITAM sequences that, when phosphorylated, associate with SYK. The
constitutive phosphorylation of the FcRγ ITAM and its association
with SYKwere observed in AML cells, suggesting its role in the tonic ac-
tivation of SYK [56].
Approximately 1/3 of patients with AML have mutations in the FLT3
gene that result in the expression of a constitutively active receptor ty-
rosine kinase. In these cells, a role for SYK also has been implicated [58].
Active, phosphorylated FLT3 physically associates with SYK through its
more C-terminal SH2 domain and SYK, in turn, enhances the activity
of FLT3 by phosphorylation. This cooperative activation of both kinases
leads to an increase in the expression of MYC and MYC target genes.
2.3. SYK fusion proteins in hematopoietic malignancies
An alternative way to generate tonic, SYK-dependent signals is
through gene rearrangements and the production of constitutively ac-
tive fusion proteins. Data generated from next generation sequencing
indicates that SYK is rarely mutated in any type of cancer [59]. Thus,
point mutations in SYK do not appear to be important drivers of tumor-
igenesis. However, chromosomal translocations involving the SYK gene
have been detected and these can result in the production of fusion pro-
teins that promote myeloproliferative or lymphoproliferative diseases.
For example, a fusion protein in which the dimerization domain of the
TEL gene product is fused to SYK results in an active kinase that
promotes a myeloproliferative disorder [60]. Constitutive activation re-
quires the TEL oligomerization domain and results in the phosphoryla-
tion on tyrosine of the fusion protein. The oligomerization of TEL-SYK
through the TEL domain likely mimics the activation of SYK that occurs
during the clustering of the receptors with it associates. This stimulates
SYK autophosphorylation on sites that modulate its activity and pro-
mote its interactions with downstream effectors that bear SH2 or func-
tionally related domains [13].
A fusion protein that contains the N-terminal Tec and PH homology
domains of the tyrosine kinase ITK fused tomost of linker B and the cat-
alytic domain of SYK is found frequently in nonspeciﬁc PTCLs. The
resulting fusion protein is constitutively active and its expression
leads to the phosphorylation of downstream adaptor and effector pro-
teins [61,62]. Unlike TEL-SYK, ITK-SYK expression selectively leads to T
cell lymphoproliferative diseases, perhaps due to a requirement for
the expression of SLP-76, which is critical for ITK-SYK activation and
the subsequent phosphorylation of either SYK or ZAP-70, which then
play important adaptor functions downstream of activated TEL-SYK
perhaps similar to the role played by ZAP-70 in B-CLL [63]. Expression
of neither the TEL-SYK nor ITK-SYK fusion protein alone is likely to be
sufﬁcient for full B or T cell transformation as recent mouse models in-
dicate that additional genetic changes are required to overcome SYK-
induced, Blimp-1-mediated terminal differentiation [64].
2.4. SYK and ITAM-signaling in non-hematopoietic malignancies
The inappropriate activation of SYK through the abnormal expres-
sion of ITAM-containing proteins can contribute to cell transformation
in non-hematopoietic cells. For example, mouse mammary tumor
virus (MMTV), which causes adenocarcinomas in mice, expresses an
env gene product that, when expressed in mammary epithelial cells, in-
duces morphological changes consistent with transformation [66]. The
Env protein contains an ITAM sequence through which it associates
Fig. 1.Mechanisms of SYK-promoted cell survival. SYK promotes the coupling of ITAM-
bearing receptors to pro-survival pathways via the modulation of protein kinase activity
( ) leading to changes in the level of key regulators of apoptosis ( ) including
increases in the production of anti-apoptotic proteins such as BCL-XL, MCL-1, BCL2A1, and
XIAP; and a decrease in the pro-apoptotic protein HRK. SYK can also promote the activa-
tion of transcription factors ( ) such as STAT3, STAT5 and SREBP and enhance
MYC-induced expression of microRNAs targeting ITIM-containing proteins such as CD22
and FCGR2B.
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ITAM tyrosines and is blocked by the SYK inhibitor, piceatannol. Similar-
ly, the ITAMof LMP2A,which contributes to cancer cell survival in PTLD,
also inﬂuences the physical properties of EBV-induced nasopharyngeal
carcinoma cells [67]. LMP2A associates with SYK via its ITAM and en-
hances motility in a manner dependent on the conserved ITAM tyro-
sines and on the expression and activity of SYK. The ectopic
expression of LMP2A in keratinocytes also promotes cell migration in
an ITAM- and SYK-dependent manner by inducing the translocation of
αV-integrin to the membrane [68]. The gene for C35 (C17orf37),
which is located on the HER2 amplicon, is increased in expression
with HER2 gene ampliﬁcation in human breast cancer [69]. C35 also
has an ITAM and its expression in mammary epithelial cells induces in-
vasive growth and triggers an epithelial-to-mesenchymal transition
(EMT) as characterized by a loss of E-cadherin. This activity requires
both the C35 ITAM sequence and SYK. It is interesting that, in many of
these same cell types, the expression of SYK in the absence of ITAM-
containing effectors like Env, LMP2A andC35 actually inhibits cellmotil-
ity and EMT (see below). Thus, these aberrantly expressed, ITAM-
containing molecules may sequester SYK away from its normal
interacting partners within the cell in much the same way that LMP2A
expression inhibits BCR signaling in EBV+ B cells. They potentially
could localize active SYK near a particular set of substrates whose phos-
phorylation alters cellular growth properties.
2.5. SYK and cell survival signaling in non-hematopoietic malignancies
Oncogenic mutations in K-Ras are seen frequently in adenocarci-
nomas of the pancreas, lung and colon. A recent analysis compared
gene expression proﬁles of lung and pancreatic cancer cells dependent
on the expression of oncogenic K-Ras for survival to tumor cells not de-
pendent on K-Ras [70]. Interestingly, SYK is the gene most commonly
expressed in K-Ras-dependent (or K-Ras addicted) cells that is missing
from K-Ras-independent cells. Accordingly, SYK protein levels are rela-
tively high in K-Ras addicted cells. In these cells, the knockdown of SYK
expression or inhibition of SYK activity results in caspase 3 activation
and cell death. The expression in many cells of oncogenes like K-Ras in-
duces apoptosis unless cells acquire additional anti-apoptotic measures
[71]. Thus, it is likely that the pro-survival activity of SYK protects these
cells from K-Ras-induced apoptosis.
A similar pro-survival role for SYK is seen in retinoblastoma [72].
Whole genome sequencing of retinoblastoma cells reveals no signiﬁcant
mutations in any oncogenes or tumor suppressor genes other than RB1.
However, many epigenetic changes in gene methylation are observed,
including reduced methylation of the SYK gene promoter. As a conse-
quence, SYK is expressed in both retinoblastoma orthotopic xenografts
and cell lines, but is actually absent from normal retina. Both the appli-
cation of SYK inhibitors and knockdown of SYK expression by shRNA re-
sult in a dramatic increase in mitochondrial-based apoptosis. The
addition of a SYK inhibitor to the chemotherapeutic regimen used to
treat retinoblastoma in a mouse model signiﬁcantly improves out-
comes, clearly suggesting SYK as a promising therapeutic target for
the treatment of childhood retinoblastoma [72]. Thus, the expression
of SYK can protect cancer cells from the pro-apoptotic consequences
of either the loss of Rb or the expression of activated K-Ras.
For many tissues—including brain, colon, kidney and ovary—the
levels of SYK mRNA are, in general, higher in cancerous than in normal
tissues [8], suggesting possible roles for the kinase in tumorigenesis in
many cell types outside of the immune system. In ovarian cancer, for ex-
ample, the expression level of SYK increases with tumor grade [73]. Tu-
mors of lowmalignant potential have lower levels of SYK, intermediate
levels are present in grade 1 tumors, and the highest levels are found in
aggressive grade 3 cancer cells. The silencing of SYK expressionmarked-
ly inhibits anchorage-independent growth and induces apoptosis in
SYK-expressing ovarian cancer cells. An analysis of genes co-expressed
in small cell lung cancer (SCLC) reveals SYK as a potential oncogenicdriver [74]. An examination of primary tumor samples found SYK pres-
ent in 11 of 33 SCLC tissues at levels much higher than those in normal
alveolar epithelium. Also, a large majority of SCLC cell lines overexpress
SYKmRNA [75]. The silencing of SYK expression by siRNA decreases cell
growth and increases apoptosis in SYK-positive SCLC cells. Similarly,
SYK is frequently found in squamous cell carcinomas of the head and
neck (SCCHN) where its expression enhances cell migration [76]. Inter-
estingly, elevated SYK expression is also observed in SCCHN patient tis-
sues where it correlates with increased metastases to the lymph nodes
and with a poor patient survival.
2.6. Mechanisms of SYK-dependent survival signaling
A fundamental hallmark of a cancer cell is its ability to resist apopto-
sis [77], a capability enhanced by the expression of Syk (Fig. 1). Signal-
ing through PI3K and AKT, known mediators of pro-survival signaling,
is thought to underlie SYK's role as a promoter of tumorigenesis in
many tumors. In normal B cells, SYK couples the antigen receptor to
the activation of the PI3K/AKT pathway [78,79]. The activation of PI3K
generates phosphatidylinositol 3,4,5-trisphosphate (PIP3), amembrane
anchor for and activator of the serine/threonine kinase, AKT. Activation
of PI3K and AKT in response to BCR-signaling is essential for the BCR-
and SYK-dependent tonic signaling that promotes cell survival in nor-
mal B cells as the death of mature B cells resulting from the induced de-
letion of the BCR can be rescued by expression of a constitutively active
form of PI3K or by deletion of PTEN [80].
AKT is a pleiotropic kinase that controls survival signaling through
the phosphorylation of multiple downstream substrates that play key
roles in regulating the activity and/or expression of pro- and/or anti-
apoptotic proteins. Multiple mechanisms are operative in different
tumor cell types. An important downstream target of pro-survival sig-
naling in B-CLL is MCL-1, an anti-apoptotic member of the Bcl-2 family
of cell death regulatory proteins [81]. The silencing of MCL-1 by RNA in-
terference leads to cell death, indicating its importance as a downstream
target of survival pathways [82]. B-CLL cells in general exhibit a SYK-
dependent increase in the basal state of phosphorylation of AKT. Acti-
vated AKT phosphorylates and inhibits glycogen synthase kinase 3
(GSK3), a negative regulator of MCL-1 protein stability. GSK3 targets
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lates its ubiquitination by the Fbw7-containing Skp1-Cullin-F-box com-
plex (SCF) to trigger subsequent proteasomal degradation [83].
Interestingly, PKCδ also is a downstream target of activated SYK in B-
CLL cells [29]. Active PKCδ promotes the activation of AKT and also func-
tions independently of AKT to inactivate GSK3 and stabilizeMCL-1. This
provides an alternative mechanism by which the level of MCL-1 can be
regulated even in subsets of B-CLL cells in which AKT is not demonstra-
bly activated. Thus, the treatment of cells with inhibitors of SYK
results in the downregulation of MCL-1 at the level of protein stability
due to an AKT and/or PKCδ-mediated inhibition of GSK3. In retinoblas-
toma, the expression of SYK also protects MCL-1 from degradation
[72], indicating that this mechanism is likely to be operative in multiple
tumor types.
Activation of the PI3K/AKT pathway also is an important promoter of
cell survival in DLBCLs, although the consequences of activation vary
with tumor type. In BCR-dependent DLBCLs exhibiting high levels of ac-
tivated NF-κB, the inhibition of SYK or PI3K attenuates the transcription
of NF-κB-regulated genes that include BCL2A1, a gene that codes for an
anti-apoptotic member of the BCL-2 family [38]. In contrast, in BCR-
dependent cells with low levels of NF-κB, BCR signaling represses the
expression of HRK, a BH3 domain-only pro-apoptotic protein [38]. In-
hibitors of either SYK or PI3K enhance the expression of HRK, which
then promotes apoptosis through its interactions with anti-apoptotic
proteins such as BCL-2 and Bcl-xL [38,84].
The expression of LMP2A in EBV-infected cells promotes cell survival
through the SYK-dependent, constitutive activation of PI3K/AKT, which
enhances the expression of the anti-apoptotic protein, BCL-XL (BCL2L1)
[85], and protects EBV+ Burkitt's lymphoma cells from MYC-induced
apoptosis [86]. In EBV+B cell lymphomas, the inhibition of SYK also re-
sults in the degradation of the caspase 3 inhibitor, XIAP [87], due to a de-
crease in the AKT-dependent inhibition of HTRA2, a protease for which
XIAP is a known substrate [52].
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase
and well known regulator of tumor growth and proliferation that is acti-
vated downstream of the PI3K/AKT pathway [88]. In AML, inhibitors or
shRNA targeting SYK suppress the activity ofmTOR,which is constitutive-
ly active in untreated cells [89]. Combinations of SYK inhibitors with in-
hibitors of PI3K or mTOR synergize to induce AML cell differentiation.
Interesting positive feed-forward signals also can be stimulated
through the PI3K/AKT pathway to enhance the efﬁciency of BCR-
signaling in some tumor cells. The BCR-mediated activation of SYK
and PI3K/AKT in DLBCLs activates the transcription factor SREBP, a key
regulator of genes required for cholesterol biosynthesis [38]. The
resulting increased expression of enzymes of the cholesterol anabolic
pathway elevates plasma membrane cholesterol, which enhances
BCR-signaling by promoting receptor clustering within cholesterol-
rich membrane microdomains or lipid rafts. Additionally, the
SYK-dependent activation of AKT and consequent inhibition of GSK3 in-
crease the intracellular level of MYC, whose degradation is enhanced
when phosphorylated by GSK3. MYC activates the miR17-92 cluster of
microRNAs, which enhance BCR signaling by downregulating the ex-
pression of inhibitory proteins including CD22 and FcγRIIb (FCGR2B)
[90]. Both CD22 and FcγRIIb contain within their cytoplasmic tails
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). ITIMs,
when phosphorylated on tyrosine, bind negative regulators of BCR sig-
naling including the lipid phosphatase SHIP1 and the tyrosine phospha-
tase SHP-1 [91]. Thus, either enhanced expression of MYC or of the
miR17-92 cluster reduces the expression of ITIM-containing proteins
to promote the BCR-dependent activation of downstream signaling ef-
fectors that include SYK, PI3K and AKT.
SYK also is tied to pro-survival pathways not directly associatedwith
increased activity of the PI3K/AKT pathway. In multiple cell types in-
cluding DLBCL, Burkitt's lymphoma, and breast carcinoma, an interac-
tion of SYK with nucleolin (NCL) promotes the binding to NCL of the
mRNA coding for the anti-apoptotic protein, BCL-XL, but not thealternatively spliced message coding for the smaller pro-apoptotic pro-
tein, BCL-XS [92]. This interaction with NCL stabilizes the BCL-XL tran-
script from being degraded in response to oxidative or genotoxic
stress. SYK also inﬂuences the activity of signal transducer and activator
of transcription (STAT) proteins, transcription factors that are activated
through phosphorylation on tyrosine. Of themanySTAT proteins, STAT3
and STAT5 in particular are key regulators of tumor cell survival [93].
Proteomic analyses of SYK-interacting proteins in AML identiﬁed both
STAT3 and STAT5 as direct binding partners of SYK [56]. Both are consti-
tutively activated and phosphorylated in AML cells in which tonic sig-
naling and SYK activation are mediated by integrins and FcRγ. The
expression of constitutively active forms of STAT3 or STAT5 rescues
AML cells from the anti-proliferative effects of inhibitors of SYK activity
or expression. Similarly, the expression in cells of the TEL-SYK fusion
protein results in the phosphorylation of STAT5 [94], while STAT3 is
phosphorylated in both B-CLL and B-ALL cells through a SYK-
dependent pathway [31,95]. Interestingly, the activation of STATs oc-
curs via pathways independent of Janus kinases (JAKs), the canonical
upstream regulators of STAT activity. Finally, in ovarian cancer cells,
SYK promotes cell survival by inhibiting the expression of C-JUN [73].
Consequently, apoptosis triggered by a loss of SYK is partially rescued
by inhibitors of JNK, the upstream activator of C-JUN.
3. SYK as a tumor suppressor
3.1. SYK and tumor suppression in B-ALL
The vast bulk of the evidence from studies on tumor cells of hemato-
poietic origins indicates that the presence of SYK and its activation are
important for cell survival and, as such, promotion of tumor growth
with one notable exception. The abnormal alternative processing of
SYKmRNA leads to a dramatic reduction in SYK expression and activity
in childhood CD19+CD10- pro-B cell ALL that likely arrests cellular
maturation at the pro-B cell to pre-pre-B cell transition. This is a rare ex-
ample where a loss of SYK contributes to malignant progression in a B
cell-derived cancer [96].
3.2. SYK and tumor suppression in carcinomas
Deﬁning a precise role for SYK in carcinomas, cancers derived from
epithelial cells, has been a complicated process. In some cell and tissue
types, SYK appears to be associated with a malignant phenotype as
discussed above. However, for many tumor types, SYK is encountered
frequently in well or moderately differentiated carcinomas, but it is ab-
sent from poorly differentiated and invasive cells. Its knockdown in
more well differentiated cancers enhances invasive growth behaviors
while its re-expression in highly malignant cancer cells retards motility
and inhibits metastasis. Thus, SYK is frequently described as a tumor
suppressor in many epithelial cell-derived cancers.
An inverse relationship between SYK expression and tumor progres-
sion was ﬁrst described by Mueller and co-workers studying a role for
the kinase inmammary carcinogenesis [97]. At both themRNA and pro-
tein levels, SYK is present in normalmammary gland epithelial cells and
in breast cancer cells of low metastatic potential, but is absent from
highly invasive, malignant cell lines. In patient samples, the loss of
SYK during tumor development is progressive with levels of the kinase
reduced in ductal carcinoma in situ (DCIS) and lost in invasive breast
cancer [19,98]. Distant metastases are more frequently encountered in
breast cancer patients with reduced levels of SYK mRNA [99]. The loss
of SYK is a consequence of both the methylation of CpG islands in the
SYK promoter and allelic loss. The SYK promoter is frequently
hypermethylated in primary breast tumors, but unmethylated in adja-
cent normal breast tissue [100]. Heterozygotic loss of the SYK gene is fre-
quent in invasive ductal carcinoma (IDC) and inDCIS located adjacent to
IDC [19]. Consequently, Syk haploinsufﬁcient mice exhibit an increased
risk of mammary tumors [20].
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differentiated cancer cells is seen in a number of different tumor tissues.
SYK is present in normal ducts and ductules in the pancreas and in well
differentiatedmalignant ducts, but is lost as pancreatic ductal adenocar-
cinoma (PDAC) cells progress through moderately differentiated to
poorly differentiated [101]. Similarly, SYK is present in differentiated
PDAC cell lines, but is absent from less differentiated lines. Interestingly,
the pancreatic and lung cancer cells dependent on K-RAS (and SYK) for
survival have a more epithelial morphology while K-RAS-independent
cells that lack SYK have a mesenchymal morphology [70]. Decreases in
the expression of SYK inmoremalignant, invasive tumor cells due to epi-
genetic silencing are also seen in bladder cancer [102], colorectal cancer
[103], melanoma [104,105], gastric cancer [106,107], nasopharyngeal
cancer [108], and hepatocellular carcinoma (HCC) [109]. Interestingly,
SYK levels are controlled also at the protein level by CHK1, which is
frequently overexpressed in HCC. CHK1 phosphorylates SYK on Ser-295
promoting its ubiquitination and proteasomal degradation [110].
Carcinomas at the primary tumor site generally have an epithelial
morphology, are tightly packed, and are characterized by the expression
of E-cadherin located at the sites of ﬁxed cell–cell junctions. The process
by which cancer cells leave the primary tumor to enter the circulation
and travel to distant sites requires a transition to amesenchymal pheno-
type characterized by a loss of cell polarity, increased motility, and en-
hanced invasive properties [111]. This epithelial-to-mesenchymal
transition (EMT) is crucial for embryogenesis and organ development,
but cancer cells use this process to initiate invasion and metastasis.
Variances in the expression of SYK in poorly versus well or moderately
differentiated tumor cells likely reﬂect intrinsic effects of the kinase
on the differentiation and physical properties of these cells that include
the regulation of EMT. The expression in immortalized, but
nontransformed, MCF10A breast epithelial cells of a shRNA targeting
SYK increases cell motility, invasion, and growth in soft agar and induces
a more ﬁbroblast-like morphology characteristic of EMT [20]. Analysis of
changes in gene expression resulting from the silencing of SYK expression
conﬁrms the loss of epithelial gene products and the increased expression
of genes characteristic of mesenchymal cells. Similarly, a catalytically in-
active form of SYK expressed in MCF7 cells acts as a dominant negative
mutant to increase tumorigenesis in amouse xenograft model [97]. Com-
parable results are observed in K-Ras addicted pancreatic carcinomas
where the knockdown of SYK expression leads to a loss of E-cadherin ex-
pression, a characteristic feature of EMT [70]. Interestingly, SYK is included
in the EMT core gene signature as a gene reduced in expression in breast
cancer cells undergoing EMT in response to multiple EMT-inducing tran-
scription factors [112]. Thus, SYK is a negative regulator of the EMT pro-
cess, which likely explains much of its differential expression in well
versus poorly differentiated tumors.
The ability of SYK to enhance and support the growth properties of
cells with an epithelial phenotype likely underlies its growth inhibitory
effects when re-expressed in more malignant, invasive mesenchymal
cells that normally lack SYK. The re-introduction of SYK into highly inva-
sive breast carcinomas reduces cell motility [113], invasive growth [97]
and slows tumor growth and inhibits metastases in animal xenograft
models [97]. Similar reductions in cell migration and invasion are seen
when SYK is re-expressed in SYK-negative hepatocellular carcinoma
[109], colorectal cancer [103], melanoma [104,105] and pancreatic ade-
nocarcinoma [101]. Gene expression analyses of SYK-negative Panc1
cells identiﬁed signiﬁcant changes in the expression of over 2000
genes resulting from the re-expression of SYK [101] including genes
such as MMP2 that are required for invasive growth. Panc1 cells in
which SYK is re-expressed develop a more differentiated phenotype
and have increased cell–cell interactions [101], which is consistent
with the ability of SYK to enhance cell–cell interactions in breast cancer
cells [113]. Rapid changes in the physical properties of cancer cells ex-
pressing SYK can be observed upon the application of inhibitors of the
kinase [113]. Thus, the negative effect of SYK on the growth properties
of metastatic tumor cells is likely a product both of SYK-dependentchanges in gene expression and the more direct effects of phosphoryla-
tion of modiﬁers of cytoskeletal dynamics [114,115]. For example, SYK
can catalyze the phosphorylation of cytoskeletal proteins such as α-
tubulin, cortactin, E-cadherin, α-catenin and MAP1B [113–117]. SYK
also is recruited to the centrosomewhere multiple substrates are locat-
ed [118,119]. It is this ability of SYK to enhance adhesion and negatively
affect motility and invasion that explains its absence from highly ag-
gressive tumor cells and underlies its classiﬁcation as a tumor suppres-
sor in certain tumor cell types.
As carcinoma cells progress to a more highly invasive phenotype, the
suppression of SYK expression and activity likely requires the upregula-
tion of additional mechanisms for survival. For example, many K-Ras-
independent carcinomas are deﬁcient in PTEN [70] and have high levels
of active AKT,which promotes cell survival. Interestingly, a fraction of pri-
maryDLBCL samples exhibit increases in the SYK gene copynumberwhile
a distinct subset exhibits a loss of PTEN [38], suggesting that bothmecha-
nisms may independently promote cell survival.
3.3. Alternative splicing of SYK
Transcription of the SYK gene gives rise to two alternatively spliced
products: full-length SYK, which is sometimes referred to as Syk(L),
and the shorter gene product SYKB, also referred to as Syk(S). SYKB
lacks a stretch of 23 amino acids in linker B, referred to as the linker in-
sert or DEL [120], and is intrinsically less active as compared to SYK in
coupling the BCR to intracellular signaling [121]. Growing evidence in-
dicates that SYK and SYKB have different effects on the growth proper-
ties of cancer cells. SYKB is found, alongwith SYK, inmany breast cancer
cell lines in which the SYK gene is not silenced, but is missing from nor-
mal breast epithelial cells [120]. Interestingly, unlike full-length SYK, the
ectopic expression of SYKB in highly invasive breast cancer cells fails to
reduce cell invasiveness [120]. Similarly, the expression pattern of SYK
versus SYKB varies in HCC. SYK levels are down-regulated in HCC
tumor samples as compared to normal liver tissue, but SYKB levels are
actually higher in HCC [122]. Since the phosphorylation site on SYK for
CHK1 is located in the DEL sequence, elevated levels of CHK1 also lead
to the selective loss of the full-length kinase while not affecting the
level of SYKB [110]. The re-expression of SYK, but not SYKB in SYK-
negative HCC cells inhibits cell growth in vitro and tumor growth and
metastasis in vivo [122]. In fact, the expression of SYKB moderately en-
hances tumor cell growth and promotes the formation of lungmetasta-
ses in mice. Of the two splice isoforms, SYKB is found preferentially in
poorly differentiated HCC cells where its presence correlates with in-
creased features of cells having undergone EMT. In fact, the expression
of SYKB is a signiﬁcant indicator of poor prognosis inHCC patients [122].
Thus, SYKB lacks the tumor suppressive activities of SYK, and its expres-
sion may actually contribute to a more highly transformed phenotype.
Even in cellswhere the overall effect of the elevated expression of SYK
enhances tumorigenesis, differences exist in the properties of the two
splice isoforms. An analysis of alternative splicing and its contributions
to tumor cell survival identiﬁed splicing of the SYK transcript as a major
contributor to ovarian cancer cell survival [73]. In this system, the induc-
tion of SYK promotes cell survival, while the manipulation of SYK gene
splicing to decrease SYK and increase SYKB induces apoptosis. While the
level of expression of SYK selectively reduces the expression of C-JUN to
inhibit apoptosis, SYK-dependent changes in anchorage-independent
growth aremore aproduct of the total level of SYK isoforms expressed. In-
terestingly, the treatment of cells with EGF selectively promotes the ex-
pression of the full-length kinase to promote cell survival.
The differential effects of SYK and SYKB on the properties of cancer
cells are generally attributed to differences in their respective localiza-
tions within the cell. Cellular fractionation and immunoﬂuorescence
studies indicate that SYK is present in both the nucleus and cytoplasm,
but SYKB is conﬁned to the cytoplasm [73,120,122]. SYK, but not
SYKB, can enter the nucleuswhere it interactswith histone deacetylases
and the transcription factor Sp1 to repress the transcription of Sp1-
Table 1
Cancer cells in which SYK functions as a tumor promoter.
Cancer type Observation Reference
B-cell lymphocytic leukemia (B-CLL) Constitutively active SYK
Inhibition of SYK induces apoptosis.
[28,31,32]
Diffuse large B-cell lymphoma (DLBCL) Constitutively active SYK, gain in gene copy number
Inhibition of SYK induces apoptosis or cell cycle arrest.
[36–38]
Follicular lymphoma (FL) SYK inhibition induces apoptosis. [41]
Mantle cell lymphoma (MCL) SYK overexpressed due to gene ampliﬁcation
Inhibition induces apoptosis.
[42]
Marginal zone lymphoma (MZL) SYK expression is upregulated. [43]
B-cell acute lymphocytic leukemia (B-ALL) Constitutively active SYK
SYK inhibitors block cell and tumor growth.
[46–48]
Peripheral T cell lymphoma (PTCL) Constitutively active SYK
TEL-SYK fusion protein
[49,62]
EBV+ post-transplant lymphoproliferative disorder (PTLD) LMP2A-mediated SYK activation
SYK inhibition induces apoptosis.
[53]
Acute myeloid leukemia (AML) Integrin-mediated SYK activation
SYK inhibition decreases proliferation and induces differentiation.
[54–56]
Nasopharyngeal carcinoma LMP2A-mediated SYK activation [65]
HER2-positive breast cancer C35-mediated SYK activation [67]
Pancreatic cancer K-Ras dependent cells
Silencing SYK results in apoptosis.
[68]
Lung cancer K-Ras dependent cells
Silencing SYK results in apoptosis.
[68]
Retinoblastoma SYK expressed in cancer cells, but not normal retina
SYK inhibition induces apoptosis.
[70]
Ovarian cancer SYK expression increases with tumor grade.
SYK inhibition induces apoptosis.
[71]
Small cell lung cancer (SCLC) Elevated SYK expression in tumors
Silencing SYK promotes apoptosis.
[72,73]
Squamous cell carcinoma of the head and neck (SCCHN) Elevated SYK expression enhances motility. [74]
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Consistent with such a mechanism, the appearance of SYK in the nucleus
is of positive prognostic signiﬁcance in gastric cancer [107].
The basis of the differential localization of SYK and SYKB is not en-
tirely clear. The DEL region resembles a bipartite nuclear localization
signal (NLS) and the replacement of basic amino acids within this se-
quence results in the exclusion of SYK from the nucleus [120]. However,
the replacement of Y290 (based on the murine Syk numbering system)
with a phenylalanine has the same effect, but this change actually con-
verts theDEL into a nuclear export sequence (NES) [124]. Attachment of
the entire linker B region, but not the DEL sequence, to a heterologous
protein can deliver it into the nucleus [120]. However, this activity
maps to a region located near the C-terminal end of the linker, well re-
moved from the DEL, which is located in the N-terminal one-third of
linker B [124]. The localization of full-length SYK itself also is subjectTable 2
Cancer cells in which SYK functions as a tumor suppressor.
Cancer type Observation
Childhood CD19+CD10− pro-B-ALL SYK loss leads to malignan
Decreased SYK correlates
Promoter methylation and
SYK re-expression inhibits
Silencing SYK induces EM
Breast cancer
Pancreatic ductal adenocarcinoma Loss of SYK in less differen
Silencing SYK induces EM
Bladder cancer
Colorectal cancer
Decreased expression of S
Decreased expression of S
Re-expression reduces mi
Melanoma Decreased expression of S
Re-expression reduces mi
Gastric cancer Decreased expression of S
Change in nuclear localiza
Nasopharyngeal cancer Decreased expression of S
Hepatocellular carcinoma Decreased expression of S
CHK1-mediated degradati
SYK re-expression inhibits
SYKB promotes metastasis
Ovarian cancer SYK promotes cell survivato regulation as integrin clustering, BCR engagement and PKC activation
result in a translocation of SYK out of the nucleus [113,124]. Regardless
of the mechanism, it is clear that an analysis of changes in the levels of
total SYK plus SYKB mRNA and/or total SYK plus SYKB protein (e.g., as
measured by immunoﬂuorescence microscopy) can be misleading
when assessing the potential involvement of SYK in modulating the
growth properties of a particular cancer type.
4. Conclusions
The ability of SYK to function as either a promoter (Table 1) or sup-
pressor (Table 2) of malignant cell growth appears to be highly depen-
dent on the cell type and its stage of differentiation, the relative levels of
the two SYK isoforms that are expressed, the mechanisms acting up-
stream of the kinase that lead to its activation, and the biological roleReference
cy.
with invasion, metastasis and tumor grade.
allelic loss
motility and metastasis.
T.
[94]
[20,95–98]
tiated tumor cells
T.
[68,99]
YK, epigenetic silencing
YK, epigenetic silencing
gration and invasion.
[100]
[101]
YK, epigenetic silencing
gration and invasion.
[102,103]
YK, epigenetic silencing
tion
[104,105]
YK, epigenetic silencing [106]
YK, epigenetic silencing
on
motility and invasion.
.
[107,108,120]
l while SYKB induces apoptosis. [71]
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growth properties primarily through three mechanisms: 1) The pres-
ence of SYK promotes cell survival by stabilizing at both the protein
and mRNA level the expression of anti-apoptotic proteins. This activity
underlies many of the tumor promoting activities of the kinase. 2) The
presence of SYK alters gene expression to affect cellular differentiation
programs that regulate EMT. This requires that SYK has the capacity to
transit from the cytoplasm into the nucleus. This activity likely explains
the differential expression of SYK between cancer cells of epithelial ver-
susmesenchymal phenotypes. 3) As a consequence of its catalytic activ-
ity, the presence of SYK alters cytoskeletal dynamics to affect cell–cell
and cell–matrix adhesion and cell motility. This activity likely underlies
many of the tumor suppressive activities of the kinase when re-
expressed in mesenchymal cells. However, the latter two functions of
SYK can be corrupted by the elevated or abnormal expression of mole-
cules bearing ITAM sequences that result in the aberrant sequestration
and relocalization of the kinase. This dual role for SYK is likely to be a
complicating factor in the development of SYK inhibitors for therapeutic
purposes as it will be important to know the exact role being played by
the kinase in the tumor cells being targeted.
Acknowledgements
Work on Syk in immune and cancer cells has been supported by the
National Institutes of Health grants R01AI098132 and R01CA115465
(R.L.G.). M.O.K. was supported by the National Science Foundation
Graduate Research Fellowship DGE-1333468.
References
[1] D.S. Krause, R.A. Van Etten, Tyrosine kinases as targets for cancer therapy, N. Engl. J.
Med. 353 (2005) 172–187.
[2] T. Hunter, Tyrosine phosphorylation: thirty years and counting, Curr. Opin. Cell
Biol. 21 (2009) 140–146.
[3] T.F. Zioncheck, M.L. Harrison, R.L. Geahlen, Puriﬁcation and characterization of a
protein-tyrosine kinase from bovine thymus, J. Biol. Chem. 261 (1986)
15637–15643.
[4] T.F. Zioncheck, M.L. Harrison, C. Isaacson, R.L. Geahlen, Generation of an active lym-
phocyte protein-tyrosine kinase by proteolysis, J. Biol. Chem. 263 (1988)
19195–19202.
[5] T. Kobayashi, S.-i. Nakamura, T. Taniguchi, H. Yamamura, Puriﬁcation and charac-
terization of a cytosolic protein-tyrosine kinase from porcine spleen, Eur. J.
Biochem. 188 (1990) 535–540.
[6] C. Wu, C. Orozco, J. Boyer, M. Leglise, J. Goodale, S. Batalov, C.L. Hodge, J. Haase, J.
Janes, J.W. Huss, A.I. Su, BioGPS: an extensible and customizable portal for querying
and organizing gene annotation resources, Genome Biol. 10 (2009) R130.
[7] A. Lal, A.E. Lash, S.F. Altschul, V. Velculescu, L. Zhang, R.E. McLendon, M.A. Marra, C.
Prange, P.J. Morin, K. Polyak, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, R.L.
Strausberg, G.J. Riggins, A public database for gene expression in human cancers,
Cancer Res. 59 (1999) 5403–5407.
[8] G. Shin, T.W. Kang, S. Yang, S.J. Baek, Y.S. Jeong, S.Y. Kim, GENT: gene expression
database of normal and tumor tissues, Cancer Informat. 10 (2011) 149–157.
[9] A. Mócsai, J. Ruland, V.L.J. Tybulewicz, The SYK tyrosine kinase: a crucial player in
diverse biological functions, Nat. Rev. Immunol. 10 (2010) 387–402.
[10] K. Sada, T. Takano, S. Yanagi, H. Yamamura, Structure and function of Syk protein-
tyrosine kinase, J. Biochem. 130 (2001) 177–186.
[11] U. Grädler, D. Schwarz, V. Dresing, D. Musil, J. Bomke, M. Frech, H. Greiner, S. Jäkel,
T. Rysiok, D.Müller-Pompalla, A.Wegener, Structural and biophysical characteriza-
tion of the Syk activation switch, J. Mol. Biol. 425 (2013) 309–333.
[12] C.L. Abram, C.A. Lowell, The expanding role for ITAM-based signaling pathways in
immune cells, Sci. STKE 377 (2007) re2.
[13] R.L. Geahlen, Syk and pTyr'd: signaling through the B cell antigen receptor,
Biochim. Biophys. Acta 1793 (2009) 1115–1127.
[14] B. Heizmann, M. Reth, S. Infantino, Syk is a dual-speciﬁcity kinase that self-
regulates the signal output from the B-cell antigen receptor, Proc. Natl. Acad. Sci.
U. S. A. 107 (2010) 18563–18568.
[15] F.M. Uckun, H. Ma, J. Zhang, Z. Ozer, S. Dovat, C. Mao, R. Ishkhanian, P. Goodman, S.
Qazi, Serine phosphorylation by SYK is critical for nuclear localization and tran-
scription factor function of Ikaros, Proc. Natl. Acad. Sci. U. S. A. 109 (2012)
18072–18077.
[16] R.L. Geahlen, Getting Syk: spleen tyrosine kinase as a therapeutic target, Trends
Pharmacol. Sci. 35 (2014) 414–422.
[17] S. Yanagi, R. Inatome, T. Takano, H. Yamamura, Syk expression and novel function
in a wide variety of tissues, Biochem. Biophys. Res. Commun. 288 (2001) 495–498.
[18] P.J. Coopman, S.C. Mueller, The Syk tyrosine kinase: a new negative regulator in
tumor growth and progression, Cancer Lett. 241 (2006) 159–173.[19] J. Blancato, A. Graves, B. Rashidi, M. Moroni, L. Tchobe, M. Ozdemirli, B. Kallakury,
K.H. Makambi, C. Marian, S.C. Mueller, SYK allelic loss and the role of Syk-
regulated genes in breast cancer survival, PLoS One 9 (2014) e87610, http://dx.
doi.org/10.1371/journal.pone.0087610.
[20] Y.M. Sung, X. Xu, J. Sun, D. Mueller, K. Sentissi, P. Johnson, E. Urbach, F. Seillier-
Moiseiwitsch, M.D. Johnson, S.C. Mueller, Tumor suppressor function of Syk in
human MCF10A in vitro and normal mouse mammary epithelium in vivo, PLoS
One 4 (2009) e7445, http://dx.doi.org/10.1371/journal.pone.0007445.
[21] J.G. Monroe, ITAM-mediated tonic signalling through pre-BCR and BCR complexes,
Nat. Rev. Immunol. 6 (2006) 283–294.
[22] M. Turner, P.J. Mee, P.S. Costello, O. Williams, A.A. Price, L.P. Duddy, M.T. Furlong,
R.L. Geahlen, V.L.J. Tybulewicz, Perinatal lethality and a block in the development
of B cells in mice lacking the tyrosine kinase p72syk, Nature 378 (1995) 298–302.
[23] F. Fallah-Arani, E. Schweighoffer, L. Vanes, V.L.J. Tybulewicz, Redundant role for
Zap70 in B cell development and activation, Eur. J. Immunol. 38 (2008) 1721-1733.
[24] K.P. Lam, R. Kuhn, K. Rajewsky, In vivo ablation of surface immunoglobulin on ma-
ture B cells by inducible gene targeting results in rapid cell death, Cell 90 (1997)
1073–1083.
[25] E. Schweighoffer, L. Vanes, J. Nys, D. Cantrell, S. McCleary, N. Smithers, V.L.J.
Tybulewicz, The BAFF receptor transduces survival signals by co-opting the B cell
receptor signaling pathway, Immunity 38 (2013) 475–488.
[26] R.M. Young, I.R. Hardy, R.L. Clarke, N. Lundy, P. Pine, B.C. Turner, T.A. Potter, Y.
Refaeli, Mouse models of non-Hodgkin lymphoma reveal Syk as an important
therapeutic target, Blood 113 (2009) 2508–2516.
[27] T.J. Kipps, Immunobiology of chronic lymphocytic leukemia, Curr. Opin. Hematol.
10 (2003) 312–318.
[28] L. Chen, L. Huynh, J. Apgar, L. Tang, L. Rassenti, A.Weiss, T.J. Kipps, ZAP-70 enhances
IgM signaling independent of its kinase activity in chronic lymphocytic leukemia,
Blood 111 (2008) 2685–2692.
[29] A.D. Baudot, P.Y. Jeandel, X. Mouska, U. Maurer, S. Tartare-Deckert, S.D. Raynaud,
J.P. Cassuto, M. Ticchioni, M. Deckert, The tyrosine kinase Syk regulates the survival
of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent
regulation of Mcl-1 expression, Oncogene 28 (2009) 3261–3273.
[30] R.C. Rickert, New insights into pre-BCR and BCR signaling with relevance to B cell
malignancies, Nat. Rev. Immunol. 12 (2013) 578–591.
[31] M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholomé, M. Burger, N. Chevalier, L.
Vallat, J. Timmer, J.G. Gribben, H. Jumaa, H. Veelken, C. Dierks, K. Zirlik, Spleen ty-
rosine kinase is overexpressed and represents a potential therapeutic target in
chronic lymphocytic leukemia, Cancer Res. 69 (2009) 5424–5432.
[32] S. Gobessi, L. Laurenti, P.G. Longo, L. Carsetti, V. Berno, S. Sica, G. Leone, D.G.
Efremov, Inhibition of constitutive and BCR-induced Syk activation downregulates
Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells, Leukemia 23
(2009) 686–697.
[33] J.W. Friedberg, J. Sharman, J. Sweetenham, P.B. Johnston, J.M. Vose, A. LaCasce, J.
Schaefer-Cutillo, S. De Vos, R. Sinha, J.P. Leonard, L.D. Cripe, S.A. Gregory, M.P.
Sterba, A.M. Lowe, R. Levy, M.A. Shipp, Inhibition of Syk with fostamatinib
disodium has signiﬁcant clinical activity in non-Hodgkin lymphoma and chronic
lymphocytic leukemia, Blood 115 (2010) 2578–2585.
[34] S. Herman, P. Barr, E. McAuley, D. Liu, Fostamatinib inhibits B-cell receptor signal-
ing, cellular activation and tumor proliferation in patients with relapsed and re-
fractory chronic lymphocytic leukemia, Leukemia 27 (2013) 1769–1773.
[35] R.E. Davis, V.N. Ngo, G. Lenz, P. Tolar, R.M. Young, P.B. Romesser, H. Kohlhammer, L.
Lamy, H. Zhao, Y. Yang, W. Xu, A.L. Shaffer, G. Wright, W. Xiao, J. Powell, J.-k. Jiang,
C.J. Thomas, A. Rosenwald, G. Ott, H.K. Muller-Hermelink, R.D. Gascoyne, J.M.
Connors, N.A. Johnson, L.M. Rimsza, E. Campo, E.S. Jaffe, W.H. Wilson, J. Delabie,
E.B. Smeland, R.I. Fisher, R.M. Braziel, R.R. Tubbs, J.R. Cook, D.D. Weisenburger,
W.C. Chan, S.K. Pierce, L.M. Staudt, Chronic active B-cell-receptor signalling in dif-
fuse large B-cell lymphoma, Nature 463 (2010) 88–92.
[36] L. Chen, S. Monti, P. Juszczynski, J. Daley, W. Chen, T.E. Witzig, T.M. Habermann, J.L.
Kutok,M.A. Shipp, SYK-dependent tonic B-cell receptor signaling is a rational treat-
ment target in diffuse large B-cell lymphoma, Blood 111 (2008) 2230–2237.
[37] S. Cheng, G. Coffey, X.H. Zhang, R. Shaknovich, Z. Song, P. Lu, A. Pandey, A.M.
Melnick, U. Sinha, Y.L. Wang, SYK inhibition and response prediction in diffuse
large B-cell lymphoma, Blood 118 (2011) 6342–6352.
[38] L. Chen, S. Monti, P. Juszczynski, J. Ouyang, B. Chapuy, D. Neuberg, J.G. Doench, A.M.
Bogusz, T.M. Habermann, A. Dogan, T.E. Witzig, J.L. Kutok, S.J. Rodig, T. Golub, M.A.
Shipp, SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways
and cholesterol biosynthesis in diffuse large B cell lymphomas, Cancer Cell 23
(2013) 826–838.
[39] P. Juszczynski, L. Chen, E. O'Donnell, J.M. Polo, S.M. Ranuncolo, R. Dalla-Favera, A.
Melnick, M.A. Shipp, BCL6 modulates tonic BCR signaling in diffuse large B-cell lym-
phomas by repressing the SYK phosphatase, PTPROt, Blood 114 (2009) 5315–5321.
[40] L. Chen, P. Juszczynski, K. Takeyama, R.C.T. Aguiar, M.A. Shipp, Protein tyrosine
phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation,
proximal B-cell-receptor signaling, and cellular proliferation, Blood 108 (2006)
3428–3433.
[41] L. Leseux, S. Hamdi, T. Saati, F. Capilla, C. Recher, G. Laurent, C. Bezombes, Syk-
dependent mTOR activation in follicular lymphoma cells, Blood 108 (2006)
4156–4162.
[42] A. Rinaldi, I. Kwee, M. Taborelli, C. Largo, S. Uccella, V.Martin, G. Poretti, G. Gaidano,
G. Calabrese, G. Martinelli, L. Baldini, G. Pruneri, C. Capella, E. Zucca, F.E. Cotter, J.C.
Cigudosa, C.V. Catapano, M.G. Tibiletti, F. Bertoni, Genomic and expression proﬁling
identiﬁes the B-cell associated tyrosine kinase Syk as a possible therapeutic target
in mantle cell lymphoma, Br. J. Haematol. 132 (2006) 303–316.
[43] E. Ruiz-Ballesteros, M. Mollejo, A. Rodriguez, F.I. Camacho, P. Algara, N. Martinez,
M. Pollán, A. Sanchez-Aguilera, J. Menarguez, E. Campo, P. Martinez, M. Mateo,
262 M.O. Krisenko, R.L. Geahlen / Biochimica et Biophysica Acta 1853 (2015) 254–263M.A. Piris, Splenic marginal zone lymphoma: proposal of new diagnostic and prog-
nostic markers identiﬁed after tissue and cDNA microarray analysis, Blood 106
(2005) 1831–1838.
[44] J. Irish, D. Czerwinski, Altered B-cell receptor signaling kinetics distinguish human
follicular lymphoma B cells from tumor-inﬁltrating nonmalignant B cells, Blood
108 (2006) 3135–3142.
[45] A.J. Arribas, C. Gómez-Abad, M. Sánchez-Beato, N. Martinez, L. DiLisio, F. Casado,
M.A. Cruz, P. Algara, M.A. Piris, M. Mollejo, Splenic marginal zone lymphoma: com-
prehensive analysis of gene expression and miRNA proﬁling, Mod. Pathol. 26
(2013) 889–901.
[46] T. Perova, I. Grandal, L.M.J. Nutter, E. Papp, I.R. Matei, J. Beyene, P.E. Kowalski, J.K.
Hitzler, M.D. Minden, C.J. Guidos, J.S. Danska, Therapeutic potential of spleen tyro-
sine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic
leukemia, Sci. Transl. Med. 6 (2014) 236ra62.
[47] F.M. Uckun, R.O. Ek, S.-T. Jan, C.-L. Chen, S. Qazi, Targeting SYK kinase-dependent
anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia
(ALL) cells with a potent SYK inhibitory pentapeptide mimic, Br. J. Haematol. 149
(2010) 508–517.
[48] F.M. Uckun, S. Qazi, I. Cely, K. Sahin, A. Shahidzadeh, I. Ozercan, Q. Yin, P. Gaynon, A.
Termuhlen, J. Cheng, S. Yiv, Nanoscale liposomal formulation of a SYK P-site inhib-
itor against B-precursor leukemia, Blood 121 (2013) 4348–4354.
[49] A. Feldman, D. Sun, M. Law, A. Novak, Overexpression of Syk tyrosine kinase in pe-
ripheral T-cell lymphomas, Leukemia 22 (2008) 1139–1143.
[50] K. Warner, N. Weit, G. Crispatzu, J. Admirand, D. Jones, M. Herling, T-cell receptor
signaling in peripheral T-cell lymphoma — a review of patterns of alterations in a
central growth regulatory pathway, Curr. Hematol. Malig. Rep. 8 (3) (2013)
163–172.
[51] M. Merchant, R. Caldwell, R. Longnecker, The LMP2A ITAM is essential for provid-
ing B cells with development and survival signals in vivo, J. Virol. 74 (2000)
9115–9124.
[52] R.G. Caldwell, J.B. Wilson, S.J. Anderson, R. Longnecker, Epstein–Barr virus LMP2A
drives B cell development and survival in the absence of normal B cell receptor sig-
nals, Immunity 9 (1998) 405–411.
[53] O. Hatton, L.K. Phillips, M. Vaysberg, J. Hurwich, S.M. Krams, O.M. Martinez,
Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-
dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote
survival of Epstein–Barr virus+(EBV+) B cell lymphomas, J. Biol. Chem. 286
(2011) 37368–37378.
[54] C.K. Hahn, J.E. Berchuck, K.N. Ross, R.M. Kakoza, K. Clauser, A.C. Schinzel, L. Ross, I.
Galinsky, T.N. Davis, S.J. Silver, D.E. Root, R.M. Stone, D.J. DeAngelo, M. Carroll, W.C.
Hahn, S.A. Carr, T.R. Golub, A.L. Kung, K. Stegmaier, Proteomic and genetic ap-
proaches identify Syk as an AML target, Cancer Cell 16 (2009) 281–294.
[55] P.G. Miller, F. Al-Shahrour, K.A. Hartwell, L.P. Chu, M. Järås, R.V. Puram, A.
Puissant, K.P. Callahan, J. Ashton, M.E. McConkey, L.P. Poveromo, G.S. Cowley,
M.G. Kharas, M. Labelle, S. Shterental, J. Fujisaki, L. Silberstein, G. Alexe, M.A.
Al-Hajj, C.A. Shelton, S.A. Armstrong, D.E. Root, D.T. Scadden, R.O. Hynes, S.
Mukherjee, K. Stegmaier, C.T. Jordan, B.L. Ebert, In vivo RNAi screening iden-
tiﬁes a leukemia-speciﬁc dependence on integrin beta 3 signaling, Cancer Cell
24 (2013) 45–58.
[56] T. Oellerich, M.F. Oellerich, M. Engelke, M. Silvia, β2 integrin-derived signals induce
cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis,
Blood 121 (2013) 3889–3899.
[57] A. Mócsai, C.L. Abram, Z. Jakus, Y. Hu, L.L. Lanier, C.A. Lowell, Integrin signaling in
neutrophils and macrophages uses adaptors containing immunoreceptor
tyrosine-based activation motifs, Nat. Immunol. 7 (2006) 1326–1333.
[58] A. Puissant, N. Fenouille, G. Alexe, Y. Pikman, C.F. Bassil, S. Mehta, J. Du, J.U. Kazi, F.
Luciano, L. Rönnstrand, A.L. Kung, J.C. Aster, I. Galinsky, R.M. Stone, D.J. DeAngelo,
M.T. Hemann, K. Stegmaier, SYK is a critical regulator of FLT3 in acute myeloid leu-
kemia, Cancer Cell 25 (2014) 226–242.
[59] J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A.
Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis
of complex cancer genomics and clinical proﬁles using the cBioPortal, Sci. Signal. 6
(2013) l1.
[60] Y. Kuno, A. Abe, N. Emi, M. Iida, T. Yokozawa, M. Towatari, M. Tanimoto, H. Saito,
Constitutive kinase activation of the TEL-Sy k fusion gene in myelodysplastic syn-
drome with t(9; 12)(q22; p12), Blood 97 (2001) 1050–1055.
[61] C. Dierks, F. Adrian, P. Fisch, H. Ma, H. Maurer, D. Herchenbach, C.U. Forster, C.
Sprissler, G. Liu, S. Rottmann, G.-R. Guo, Z. Katja, H. Veelken, M. Warmuth, The
ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice
mimicking human disease, Cancer Res. 70 (2010) 6193–6204.
[62] K. Pechloff, J. Holch, U. Ferch, M. Schweneker, K. Brunner, M. Kremer, T.
Sparwasser, L. Quintanilla-Martinez, U. Zimber-Strobl, B. Streubel, A. Gewies, C.
Peschel, J. Ruland, The fusion kinase ITK-SYK mimics a T cell receptor signal and
drives oncogenesis in conditional mouse models of peripheral T cell lymphoma,
J. Exp. Med. 207 (2010) 1031–1044.
[63] A. Hussain, D.K. Mohammad, M.O. Gustafsson, M. Uslu, A. Hamasy, B.F. Nore, A.J.
Mohamed, C.I.E. Smith, Signaling of the ITK (interleukin 2-inducible T cell ki-
nase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76
and on the adapter function of the kinases SYK and ZAP70, J. Biol. Chem. 288
(2013) 7338–7350.
[64] E. Hug, E. Hobeika, M. Reth, H. Jumaa, Inducible expression of hyperactive Syk in B
cells activates Blimp-1-dependent terminal differentiation, Oncogene 33 (2014)
3730–3741.
[65] M.P. Bach, E. Hug, M. Werner, J. Holch, C. Sprissler, K. Pechloff, K. Zirlik, R. Zeiser, C.
Dierks, J. Ruland, H. Jumaa, Premature terminal differentiation protects from
deregulated lymphocyte activation by ITK-Syk, J. Immunol. 192 (2014) 1024–1033.[66] E. Katz, M.H. Lareef, J.C. Rassa, S.M. Grande, L.B. King, J. Russo, S.R. Ross, J.G. Monroe,
MMTV Env encodes an ITAM responsible for transformation of mammary epithe-
lial cells in three-dimensional culture, J. Exp. Med. 201 (2005) 431–439.
[67] J. Lu, W.-H. Lin, S.-Y. Chen, R. Longnecker, S.-C. Tsai, C.-L. Chen, C.-H. Tsai, Syk tyro-
sine kinase mediates Epstein–Barr virus latent membrane protein 2A-induced cell
migration in epithelial cells, J. Biol. Chem. 281 (2006) 8806–8814.
[68] J.A. Fotheringham, N.E. Coalson, N. Raab-Traub, Epstein–Barr virus latent mem-
brane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration
through αV-integrin membrane translocation, J. Virol. 86 (2012) 10308–10320.
[69] E. Katz, S. Dubois-Marshall, A.H. Sims, D. Faratian, J. Li, E.S. Smith, J.A. Quinn, M.
Edward, R.R. Meehan, E.E. Evans, S.P. Langdon, D.J. Harrison, A gene on the HER2
amplicon, C35, is an oncogene in breast cancer whose actions are prevented by in-
hibition of Syk, Br. J. Cancer 103 (2010) 401–410.
[70] A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, J. Settleman,
A gene expression signature associated with “K-Ras addiction” reveals regulators
of EMT and tumor cell survival, Cancer Cell 15 (2009) 489–500.
[71] S.W. Lowe, E. Cepero, G. Evan, Intrinsic tumour suppression, Nature 432 (2004)
307–315.
[72] J. Zhang, C.A. Benavente, J. McEvoy, J. Flores-Otero2, L. Ding, X. Chen, A. Ulyanov, G.
Wu, M. Wilson, J. Wang, R. Brennan, M. Rusch, A.L. Manning, J. Ma, J. Easton, S.
Shurtleff, C. Mullighan, S. Pounds, S. Mukatira, P. Gupta, G. Neale, D. Zhao, C. Lu,
R.S. Fulton, L.L. Fulton, X. Hong, D.J. Dooling, K. Ochoa, C. Naeve, N.J. Dyson, E.R.
Mardis, A. Bahrami, D. Ellison, R.K. Wilson, J. Downing, M.A. Dyer, A Novel retino-
blastoma therapy from genomic and epigenetic analyses, Nature 481 (2012)
329–334.
[73] P. Prinos, D. Garneau, J.-F. Lucier, D. Gendron, S. Couture, M. Boivin, J.-P.
Brosseau1, E. Lapointe, P. Thibault, M. Durand, K. Tremblay, J. Gervais-Bird, H.
Nwilati, R. Klinck, B. Chabot, J.-P. Perreault, R.J. Wellinger, S.A. Elela, Alternative
splicing of SYK regulates mitosis and cell survival, Nat. Struct. Mol. Biol. 18
(2011) 673–679.
[74] A.R. Udyavar, M.D. Hoeksema, J.E. Clark, Y. Zou, Z. Tang, Z. Li, M. Li, H. Chen, A.
Statnikov, Y. Shyr, D.C. Liebler, J. Field, R. Eisenberg, L. Estrada, P.P. Massion, V.
Quaranta, Co-expression network analysis identiﬁes Spleen Tyrosine Kinase
(SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer, BMC
Syst. Biol. 7 (Suppl. 5) (2013) S1.
[75] J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J.
Wilson, J. Lehár, G.V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M.F. Berger,
J.E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F.A. Mapa, J.
Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I.H. Engels, J. Cheng, G.K. Yu, J.
Yu, P. Aspesi, M. de Silva, K. Jagtap, M.D. Jones, L. Wang, C. Hatton, E.
Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R.C. Onofrio, T. Liefeld, L.
MacConaill, W. Winckler, M. Reich, N. Li, J.P. Mesirov, S.B. Gabriel, G. Getz, K.
Ardlie, V. Chan, V.E. Myer, B.L. Weber, J. Porter, M. Warmuth, P. Finan, J.L. Harris,
M. Meyerson, T.R. Golub, M.P. Morrissey, W.R. Sellers, R. Schlegel, L.A. Garraway,
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer
drug sensitivity, Nature 483 (2013) 603–607.
[76] S. Luangdilok, C. Box, L. Patterson, W. Court, K. Harrington, L. Pitkin, P. Rhys-Evans,
P. O-charoenrat, S. Eccles, Syk tyrosine kinase is linked to cell motility and
progressin in squamous cell carcinomas of the head and neck, Cancer Res. 67
(2007) 7907–7916.
[77] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144
(2011) 646–674.
[78] L.O. Beitz, D.A. Fruman, T. Kurosaki, L.C. Cantley, A.M. Scharenberg, Syk is upstream
of phosphoinositide 3-kinase in B cell receptor signaling, J. Biol. Chem. 274 (1999)
32662–32666.
[79] I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-kinase-AKT pathway in human
cancer, Nat. Rev. Cancer 2 (2002) 489–501.
[80] L. Srinivasan, Y. Sasaki, D.P. Calado, B. Zhang, J.H. Paik, R.A. DePinho, J.L. Kutok, J.F.
Kearney, K.L. Otipoby, K. Rajewsky, PI3 kinase signals BCR-dependentmature B cell
survival, Cell 139 (2009) 573–586.
[81] R.J. Youle, A. Strasser, The BCL-2 protein family: opposing activities that mediate
cell death, Nat. Rev. Mol. Cell Biol. 9 (2008) 47–59.
[82] P. Longo, L. Laurenti, S. Gobessi, The Akt/Mcl-1 pathway plays a prominent role in
mediating antiapoptotic signals downstream of the B-cell receptor in chronic lym-
phocytic leukemia B cells, Blood 111 (2008) 846–855.
[83] H. Inuzuka, H. Fukushima, S. Shaik, P. Liu, Mcl-1 ubiquitination and destruction,
Oncotarget 2 (2011) 239–244.
[84] N. Inohara, L. Ding, S. Chen, G. Núñez, Harakiri, a novel regulator of cell death, en-
codes a protein that activates apoptosis and interacts selectively with survival-
promoting proteins Bcl-2 and Bcl-X(L), EMBO J. 16 (1997) 1686–1694.
[85] T. Portis, R. Longnecker, Epstein–Barr virus (EBV) LMP2A mediates B-lymphocyte
survival through constitutive activation of the Ras/PI3K/Akt pathway, Oncogene
23 (2004) 8619–8628.
[86] K.T. Bieging, M. Swanson-Mungerson, A.C. Amick, R. Longnecker, Epstein–Barr
virus in Burkitt's lymphoma: a role for latent membrane protein 2A, Cell Cycle 9
(2010) 901–908.
[87] M. Holcki, R.G. Korneluk, XIAP, the guardian angel, Nat. Rev. Mol. Cell Biol. 2 (2001)
550–556.
[88] Y. Mamane, E. Petroulakis, O. LeBacquer, N. Sonenberg, mTOR, translation initiation
and cancer, Oncogene 25 (2006) 6416–6422.
[89] J. Carnevale, L. Ross, A. Puissant, V. Banerji, SYK regulates mTOR signaling in AML,
Leukemia 27 (2013) 2118–2128.
[90] J.N. Psathas, P.J. Doonan, P. Raman, B.D. Freedman, A.J. Minn, A. Thomas-
Tikhonenko, The Myc-miR-17-92 axis ampliﬁes B-cell receptor signaling via inhi-
bition of ITIM proteins: a novel lymphomagenic feed-forward loop, Blood 122
(2013) 4220–4229.
263M.O. Krisenko, R.L. Geahlen / Biochimica et Biophysica Acta 1853 (2015) 254–263[91] L. Nitschke, The role of CD22 and other inhibitory co-receptors in B-cell activation,
Curr. Opin. Immunol. 17 (2005) 290–297.
[92] W.-H. Wang, M.O. Childress, R.L. Geahlen, Syk interacts with and phosphorylates
nucleolin to stabilize Bcl-xL mRNA and promote cell survival, Mol. Cell. Biol. 34
(2014) 3788–3799.
[93] H. Yu, R. Jove, The STATs of cancer-new molecular targets come of age, Nat. Rev.
Cancer 4 (2004) 97–105.
[94] T. Kanie, A. Abe, T. Matsuda, Y. Kuno, M. Towatari, T. Yamamoto, H. Saito, N. Emi, T.
Naoe, TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-
independent STAT5 signal pathways, Leukemia 18 (2004) 548–555.
[95] F.M. Uckun, S. Qazi, H. Ma, L. Tuel-Ahlgren, Z. Ozer, STAT3 is a substrate of SYK ty-
rosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress,
Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 2902–2907.
[96] P.A. Goodman, C.M. Wood, A. Vassilev, C. Mao, F.M. Uckun, Spleen tyrosine kinase
(Syk) deﬁciency in childhood pro-B cell acute lymphoblastic leukemia, Oncogene
20 (2001) 3969–3978.
[97] P.J. Coopman, M.T. Do, M. Barth, E.T. Bowden, A.J. Hayes, E. Basyuk, J.K. Blancato,
P.R. Vezza, S.W. McLeskey, P.H. Mangeat, S.C. Mueller, The Syk tyrosine kinase sup-
presses malignant growth of human breast cancer cells, Nature 406 (2000)
742–747.
[98] M. Moroni, V. Soldatenkov, L. Zhang, Y. Zhang, G. Stoica, E. Gehan, B. Rashidi, B.
Singh, M. Ozdemirli, S.C. Mueller, Progressive loss of Syk and abnormal prolifera-
tion in breast cancer cells, Cancer Res. 64 (2004) 7346–7354.
[99] T. Toyama, H. Iwase, H. Yamashita, Y. Hara, Y. Omoto, H. Sugiura, Z. Zhang, Y. Fujii,
Reduced expression of the Syk gene is correlated with poor prognosis in human
breast cancer, Cancer Lett. 189 (2003) 97–102.
[100] Y. Yuan, R. Mendez, A. Sahin, J.L. Dai, Hypermethylation leads to silencing of the
SYK gene in human breast cancer, Cancer Res. 61 (2001) 5558–5561.
[101] T. Layton, C. Stalens, F. Gunderson, S. Goodison, S. Silletti, Syk tyrosine kinase acts
as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth
and invasion, Am. J. Pathol. 175 (2009) 2625–2636.
[102] E. Kunze, M. Wendt, T. Schlott, Promoter hypermethylation of the 14-3-3 sigma,
SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder car-
cinomas and associated with progression of transitional cell carcinomas, Int. J. Mol.
Med. 18 (2006) 547–557.
[103] Z. Yang, L. Huo, H. Chen, B. Ni, J. Xiang, L. Kang, L. Wang, J. Peng, Y. Yuan, J. Wang,
Hypermethylation and prognostic implication of Syk gene in human colorectal
cancer, Med. Oncol. 30 (2013) 586.
[104] C. Hoeller, C. Thallinger, B. Pratscher, M.D. Bister, N. Schicher, R. Loewe, E. Heere-
Ress, F. Roka, V. Sexl, H. Pehamberger, The non-receptor-associated tyrosine kinase
Syk is a regulator of metastatic behavior in human melanoma cells, J. Invest.
Dermatol. 124 (2005) 1293–1299.
[105] V. Muthusamy, S. Duraisamy, C.M. Bradbury, C. Hobbs, D.P. Curley, B. Nelson, M.
Bosenberg, Epigenetic silencing of novel tumor suppressors in malignant melano-
ma, Cancer Res. 66 (2006) 11187–11193.
[106] S. Wang, Y.-B. Ding, G.-Y. Chen, J.-G. Xia, Z.-Y.Wu, Hypermethylation of Syk gene in
promoter region associated with oncogenesis and metastasis of gastric carcinoma,
World J. Gastroenterol. 10 (2004) 1815–1818.
[107] H. Nakashima, S. Natsugoe, S. Ishigami, H. Okumura, M. Matsumoto, S. Hokita, T.
Aikou, Clinical signiﬁcance of nuclear expression of spleen tyrosine kinase (Syk)
in gastric cancer, Cancer Lett. 236 (2006) 89–94.
[108] Q. Jin, C. Liu, C. Yan, B. Tao, Z. Li, Z. Cai, 5-aza-CdR induces the demethylation of Syk
promoter in nasopharyngeal carcinoma cell, Gene 511 (2012) 224–226.[109] Y. Yuan, J. Wang, J. Li, L. Wang, M. Li, Z. Yang, C. Zhang, J.L. Dai, Frequent epigenetic
inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma,
Clin. Cancer Res. 12 (2006) 6687–6695.
[110] J. Hong, K. Hu, Y. Yuan, Y. Sang, Q. Bu, G. Chen, L. Yang, B. Li, P. Huang, D. Chen, Y.
Liang, R. Zhang, J. Pan, Y.-X. Zeng, T. Kang, CHK1 targets spleen tyrosine kinase
(L) for proteolysis in hepatocellular carcinoma, J. Clin. Invest. 122 (2012)
2165–2175.
[111] R. Kalluri, R.A. Weinberg, The basics of epithelial–mesenchymal transition, J. Clin.
Invest. 119 (2009) 1420–1428.
[112] J.H. Taube, J.I. Herschkowitz, K. Komurov, A.Y. Zhou, S. Gupta, J. Yang, K. Hartwell,
T.T. Onder, P.B. Gupta, K.W. Evans, B.G. Hollier, P.T. Ram, E.S. Lander, J.M. Rosen,
R.A. Weinberg, S.A. Mania, Core epithelial-to-mesenchymal transition interactome
gene-expression signature is associated with claudin-low and metaplastic breast
cancer subtypes, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) (19132-19132).
[113] X. Zhang, U. Shrikhande, Q. Zhou, R.L. Geahlen, A role for the protein-tyrosine ki-
nase, Syk, in regulating cell–cell adhesion and motility in breast cancer cells, Mol.
Cancer Res. 7 (2009) 634–644.
[114] R.M. Larive, S. Urbach, J. Poncet, P. Jouin, G. Mascré, A. Sahuquet, P.H. Mangeat, P.J.
Coopman, N. Bettache, Phosphoproteomic analysis of Syk kinase signaling in
human cancer cells reveals its role in cell–cell adhesion, Oncogene 28 (2009)
2337–2347.
[115] M.O. Krisenko, A. Cartagena, A. Raman, R.L. Geahlen, Nanomechanical property
maps of breast cancer cells as determined by multiharmonic atomic force micros-
copy reveal Syk-dependent changes in microtubule stability mediated by MAP1B,
Biochemistry (2014) (in press).
[116] S. Maruyama, T. Kurosaki, K. Sada, Y. Yamanashi, T. Yamamoto, H. Yamamura,
Physical and functional association of cortactin with Syk in human leukemic cell
line K562, J. Biol. Chem. 271 (1996) 6631–6635.
[117] J.D. Peters, M.T. Furlong, D.J. Asai, M.L. Harrison, R.L. Geahlen, Syk, activated by
cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts
with and phosphorylates α-tubulin on tyrosine, J. Biol. Chem. 271 (1996)
4755–4762.
[118] D. Zyss, P. Montcourrier, B. Vidal, C. Anguille, F. Mérezègue, A. Sahuquet, P.H.
Mangeat, P.J. Coopman, The Syk tyrosine kinase localizes to the centrosomes and
negatively affects mitotic progression, Cancer Res. 65 (2005) 10872–10880.
[119] L. Xue,W.-H.Wang, A. Iliuk, L. Hu, J.A. Galan, S. Yu, M. Hans, R.L. Geahlen, W.A. Tao,
Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase
substrates, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 5615–5620.
[120] L. Wang, L. Duke, P. Zhang, Alternative splicing disrupts a nuclear localization sig-
nal in spleen tyrosine kinase that is required for invasion suppression in breast
cancer, Cancer Res. 63 (2003) 4724–4730.
[121] S. Latour, L.M.L. Chow, A. Veillette, Differential intrinsic enzymatic activity of Syk
and Zap-70 protein-tyrosine kinases, J. Biol. Chem. 271 (1996) 22782–22790.
[122] J. Hong, Y. Yuan, J.Wang, Y. Liao, R. Zou, C. Zhu, B. Li, Y. Liang, P. Huang, Z.Wang,W.
Lin, Y. Zeng, J.L. Dai, R.T. Chung, Expression of variant isoforms of the tyrosine ki-
nase SYK determines the prognosis of hepatocellular carcinoma, Cancer Res. 74
(2014) 1845–1856.
[123] L. Wang, E. Devarajan, J. He, S.P. Reddy, J.L. Dai, Transcription repressor activity of
spleen tyrosine kinase mediates breast tumor suppression, Cancer Res. 65 (2005)
10289–10297.
[124] F. Zhou, J. Hu, H. Ma, M.L. Harrison, R.L. Geahlen, Nucleocytoplasmic trafﬁcking of
the Syk protein-tyrosine kinase, Mol. Cell. Biol. 26 (2006) 3478–3491.
